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Abstract Psoriasis vulgaris is a common and chronic
inﬂammatory skin disease which has the potential to sig-
niﬁcantly reduce the quality of life in severely affected
patients. The incidence of psoriasis in Western industrial-
ized countries ranges from 1.5 to 2%. Despite the large
variety of treatment options available, patient surveys have
revealed insufﬁcient satisfaction with the efﬁcacy of
available treatments and a high rate of medication non-
compliance. To optimize the treatment of psoriasis in
Germany, the Deutsche Dermatologische Gesellschaft and
the Berufsverband Deutscher Dermatologen (BVDD) have
initiated a project to develop evidence-based guidelines for
the management of psoriasis. The guidelines focus on
induction therapy in cases of mild, moderate, and severe
plaque-type psoriasis in adults. The short version of the
guidelines reported here consist of a series of therapeutic
recommendations that are based on a systematic literature
search and subsequent discussion with experts in the ﬁeld;
they have been approved by a team of dermatology experts.
In addition to the therapeutic recommendations provided in
this short version, the full version of the guidelines includes
information on contraindications, adverse events, drug
interactions, practicality, and costs as well as detailed
information on how best to apply the treatments described
(for full version, please see Nast et al., JDDG, Suppl 2:S1–
S126, 2006;o rhttp://www.psoriasis-leitlinie.de).
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Introduction
The Deutsche Dermatologische Gesellschaft (DDG) and
the Berufsverband Deutscher Dermatologen (BVDD) have
initiated a project to develop evidence-based guidelines for
the treatment of plaque psoriasis. The full version of the
Guidelines has been published in the Journal der Deutschen
Dermatologischen Gesellschaft (JDDG 2006 Suppl 2) and
is available at http://www.psoriasis-leitlinie.de [149]. This
article summarizes the key points of the Guidelines.
Background
Psoriasis vulgaris is a common and chronic inﬂammatory
skin disease which has the potential to signiﬁcantly reduce
the quality of life in severely affected patients. The incidence
ofpsoriasisinWesternindustrializedcountriesis1.5–2%[2].
Studies on the impairment of life quality have shown that,
depending on the severity of the disease, a signiﬁcant burden
may exist in the form of a disability or psychosocial stig-
matization [3]. Patient surveys have shown that the mental
and physical impairment associated with psoriasis is com-
parable tothatof other signiﬁcant chronic conditions, such as
type 2 diabetes or chronic respiratory diseases [4].
Patient surveys have shown that only 25% of psoriasis
patients are highly satisﬁed with the outcome of their
treatment, another 50% indicate moderate satisfaction, and
approximately 20% report low treatment satisfaction [5]. In
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of medication of up to 40% [1].
Experience has shown that treatment selection for
patients with psoriasis vulgaris is more commonly based on
traditional concepts than on evidence-based data on the
efﬁcacy of various therapeutic options. In addition, it ap-
pears that systemic therapies are occasionally not applied
in situations where they are needed due to the increased
effort involved in monitoring the patients for unwanted
side effects and possible interactions with other drugs.
Goal of the Guidelines
The overall objective of the Guidelines is to provide der-
matologists in clinics and private practice with an accepted
and evidence-based decision-making tool for the selection
and implementation of a suitable and efﬁcacious treatment
for patients with psoriasis vulgaris. The focus of the
Guidelines is on the induction therapy of mild, moderate,
and severe plaque-type psoriasis in adults.
1. Physicians’ personal experiences and traditional thera-
peutic concepts should be supplemented and, if neces-
sary, replaced by an evidence-based assessment of the
efﬁcacy of individual therapies in psoriasis vulgaris.
2. The guidelines provide in-depth explanations of the
available systemic and topical treatments for psoriasis,
including the different photo- and photochemical
therapies, and provide detailed descriptions of the
administration and safety aspects.
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1233. By providing background information on the proﬁle of
the available drugs, including efﬁcacy, safety, and
aspects of practicality and costs, the Guidelines should
facilitate the process of selecting an appropriate
treatment for each individual patient. This should help
increase compliance and optimize the beneﬁt/risk ratio
of psoriasis therapies.
Methods
A detailed description of the methodology employed in
developing the Guidelines can be found in the Method
ReportontheGuidelines(http://www.psoriasis-leitlinie.de).
Basis of data
A systematic search of the literature was carried out in May
2005 with the objective of assessing the effectiveness of
individual therapeutic options. This search yielded 6,224
publications of which 142 studies fulﬁlled the inclusion
criteria for the Guidelines (see Box 1) and were therefore
included in the assessment of the effectiveness of the rel-
evant treatment. Various other aspects were evaluated on
the basis of information presented in available literature,
without a systematic analysis, and the years of personal
experience of the experts.
Box 1 Studies had to fulfill the following criteria to be consid-
ered for the Guidelines’ recommendations
•  prospective study 
•  interim results <16 weeks 
•  exclusively adults 
• ≥75% chronic plaque psoriasis
•  severity of the skin lesions is described 
•  clear description of co-medication 
•  plausible dosage 
•  clear definition of effective outcome measures 
Evidence assessment
The efﬁcacy and effectiveness of each intervention was
evaluated using evidence-based criteria.
The methodological quality of each individual study was
assessed using the following grades of evidence (GE):
A1 Meta-analysis that includes at least one randomized
study with grade A2 evidence. In addition, the results
of the different studies included in the meta-analysis
must be consistent with one another.
A2 A high-quality (e.g. sample-size calculation, ﬂow
chart, intention-to-treat (ITT) analysis, sufﬁcient size)
randomized, double-blind comparative clinical study.
B Randomized clinical study of lesser quality or other
comparative study (non-randomized, cohort, or case-
control study).
C Non-comparative study.
D Expert opinion.
Individual interventions (i.e., as monotherapy) were rated
according to the following levels of evidence (LE):
1. Intervention is supported by studies with grade A1
evidence or studies with grade A2 evidence whose
results are predominantly consistent with one another.
2. Intervention is supported by studies with grade A2
evidence or studies with grade B evidence whose re-
sults are predominantly consistent with one another.
3. Intervention is supported by studies with grade B
evidence or studies with grade C evidence whose re-
sults are predominantly consistent with one another.
4. Little or no systematic empirical evidence
Passages requiring consensus 
The Guidelines Group defined particularly relevant 
sections as passages requiring consensus and appro-
ved these in the framework of the consensus confere-
nces. These sections are highlighted in grey boxes.       
Therapeutic recommendation
A distinct rating of the therapeutic options or a strict
clinical algorithm cannot be deﬁned for the treatment of
psoriasis vulgaris. The criteria for selecting a particular
therapy are complex. The decision for a speciﬁc treatment
should be based on the proﬁle of the available drugs and
the characteristics of a given patient. The decision for or
against a therapy remains a case-by-case decision. These
Guidelines provide a reasonable form of assistance in
deciding on a suitable therapy and are an instrument for
optimizing the required therapeutic process.
The recommendations formulated in the text are sup-
ported graphically in selected key recommendations by the
following indications of the strength of the therapeutic
recommendation:
›› Measure is highly recommended
› Measure is recommended
ﬁ Neutral
ﬂ Measure is not recommended
ﬂﬂ Measure is highly inadvisable
The strength of the recommendation reﬂects both a
treatment’s efﬁcacy and the level of evidence supporting
it as well as aspects of safety, practicality, and the cost/
beneﬁt ratio. A consensus on the strength of the recom-
mendation was reached during the Consensus Conference.
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Therapeutic options are named and discussed in alphabet-
ical order.
Therapeutic strategies
Chronic plaque–
type psoriasis
topical
therapy
systemic
therapy
Cortico-
steroids
Tazarotene
Fumaric
Acid Esters
Retinoids
Etanercept
CoalTar
Laser 
Dithranol
Calcineurin
inhibitors
combined:
climate/
balneotherapy
Vitamin D3
combined:
psychosocial
therapy
mild
BSA < 10%
PASI < 10 P.
moderate
BSA > 10%
PASI > 10 P.
Efalizumab
Infliximab
basic
therapy
+ topical therapy
UV
Cyclosporine
Methotrexate severe  
Fig. 1 Overview of the therapeutic options evaluated for chronic
plaque psoriasis (the therapeutic options are listed alphabetically and
do not represent a ranking)
Evaluation of topical and systemic therapies
in tabular form
These tables are intended to provide a rough orientation for
evaluating the therapeutic options. Cumulative calculations
of the individual aspects for the overall evaluation of the
therapeutic options are not possible and cannot be drawn
upon for the ﬁnal analysis of a therapeutic option. The
product assessment for each individual patient may deviate
greatly. A direct comparison between systemic and topical
therapies is not possible because of the different severity of
the psoriasis lesions of patients treated with topical or
systemic treatments. The evaluations reported here were
made on the basis of data extracted from the literature and
expert opinions.
For further details refer to the Methods Report at
www.psoriasis-leitlinie.de
Topical monotherapy
Therapy
Efficacy
Level
of
evidence
Safety/Tolerance in
induction
therapy
Safety/Tolerance in
maintenance
therapy
Practicality (patient)
Practicality (physician)
Cost/
Benefit
 Calcineurin
 Inhibitors
no
assessment 4+ +
not 
indicated ++ ++
no 
assessment
 Coal Tar+ / - 4 +
not 
indicated -+ / - -
Corticosteroids ++++ 
3) 1 +++ + ++ +++ +++
 Dithranol ++ 2 ++
not 
indicated
+
1)
-
2)
+
1)
-
2) +++
 Tazarotene ++ 2 ++ ++ ++ ++ ++
  Vitamin D3 -
  Analogues
+++ 1 +++ +++ ++ +++ ++
     poor     good
      -   +/-        +       ++       +++     ++++
1) inpatient
2) outpatient
3)
Global 
consideration:
potent (e.g. betamethason) or  very potent corticosteroid (e.g. 
clobetasol), also valid for fix-combinations (vitamin D plus potent 
corticosteroids)
Phototherapy and systemic monotherapy
Therapy
Efficacy
Level
of
evidence
a
S
fety/T
l
o
erance in
induction
therapy
a
S
fety/Tolerance
in
maintenance
therapy
Practicality (patient)
r
P
acticality
(p
y
h
sician)
Cost/
Benefit
y
p
a
r
e
h
t
o
t
o
h
P
 UVB +++ 2 +++
not 
indicated +/- + ++
 PUVA
+++ to 
++++ 2
+
1)
++
2)
not 
indicated -+ / - + +
+3 + + ++ + + / -
 Efalizumab + 1 ++ ++ +++ + +
 Etanercept
+
4)
++
5) 1+ + + ++ + + + +
 Infliximab +++ to 
++++
1 + ++ +++ +/- +
++ to    
+++ 1 + + +++ ++ ++
++ 2 + +++ ++ +++ +++
++ 3 + + ++ ++ +++
       poor good
       -    +/-      +  ++       +++ ++++
1) systemic PUVA
2) Bath- / Cream- PUVA
3) for women in childbearing age the therapy with retinoids
is generally not recommended
4) for 2x25mg
5) for 2x50mg
y
p
a
r
e
h
t
o
t
o
h
P
Global 
consideration:
 Acitretin 
3)
s
c
i
g
o
l
o
i
B
 Cyclosporine
 Fumaric Acid
 Esters
 Methotrexate
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123(a) Efﬁcacy The evaluation of the efﬁcacy column re-
ﬂects the percentage of patients who achieved a reduction
in the baseline Psoriasis Area and Severity Index (PASI) of
‡75%.
Scale Systemic therapy Topical therapy
++++ Approx. 90% Approx. 60%
+++ Approx. 70% Approx. 45%
++ Approx. 50% Approx. 30%
+ Approx. 30% Approx. 15%
+/– Approx. 10% Approx. 5%
– Not deﬁned Not deﬁned
The evidence level applies only to the estimate of efﬁ-
cacy.
(b) Safety/tolerance in induction therapy or mainte-
nance therapy This refers to the risk of occurrence of se-
vere adverse drug reactions or the probability of adverse
drug reactions that would result in the discontinuation of
therapy.
(c) Practicality (Patient) This evaluation analyzes the
effort involved in handling and administrating the treat-
ment regimen by the patient.
(d) Practicality (Physician) This aspect considers the
amount of work (documentation, explanation, monitoring),
personnel and equipment needs, time for physician/patient
interaction, remuneration of therapeutic measures, invoic-
ing difﬁculties/risk of recourse claims from the health
insurance companies.
(e) Cost/beneﬁt Consideration of the costs of an induc-
tion therapy or a maintenance therapy.
The evaluations of safety/tolerance in induction therapy
or maintenance therapy as well as practicality for the
physician or patient and the cost/beneﬁt were performed
using a scale ranging from poor (–) to good (++++). The
gradation between these two extremes was made based on
expert opinion and unsystematic literature search. A level
of evidence was not given for these evaluations since no
systematic literature review was performed.
Evaluation of topical therapies
Calcineurin inhibitors
Table 1 Tabular summary
Calcineurin inhibitors
First approved in Germany
Pimecrolimus (Elidel
 ) 2002 (Atopic dermatitis, not approved
for psoriasis vulgaris)
Tacrolimus (Protopic
 ) 2002 (Atopic dermatitis, not approved
for psoriasis vulgaris)
Recommended initial
dosage
Pimecrolimus cream: 1· to 2· daily
Tacrolimus: 1· to 2· daily (application
on the face: Begin with 0.03% salve;
increase later dosage to 0.1% salve)
Recommended
maintenance dosage
Individual therapeutic adjustment
Expected beginning
of clinical effect
After approximately 2 weeks
Response rate No data available
Important
contraindications
Pregnancy and nursing (due to lack of
experience) skin infections, immune
suppression
Important adverse drug
reactions (ADRs)
Burning sensation on skin, skin
infections
Important drug
interactions
None known
Other Cave: Do not combine with
phototherapy! Photoprotection!
General assessment 
Of the three studies with topical calcineurin inhibitors (pime-
crolimus, tacrolimus) assessed, one study met the inclusion criteria 
of the Guidelines.
[6] For that reason, the efficacy of psoriasis vul-
garis treatment with topical calcineurin inhibitors can currently only 
be rated with a level of evidence of 4. Based on the studies to date, 
there is no evidence that monotherapy with calcineurin inhibitors is 
beneficial. Other studies have, however, demonstrated that topical 
calcineurin inhibitors can be beneficial in the treatment of psoriasis 
vulgaris in corticosteroid-sensitive areas such as the face, intertrigi-
nous areas, and the anogenital region. 
Since topical calcineurin inhibitors are not approved treatment for 
psoriasis vulgaris, treatment may only be performed in off-label 
use. 
The tolerance is generally good. Data on long-term safety are not 
available due to the relatively short-period of availability. 
Broad usage as a first-line therapy does not appear to be justified by 
the existing data. 
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Pimecrolimus and tacrolimus administered topically 1× 
to 2× per day can be considered to be a reasonable sup-
plementary treatment of psoriasis vulgaris at specific 
locations of the body, such as the face, intertriginous 
areas and anogenital region (e.g. in interval therapy) or as 
a replacement for topical corticosteroids. 
Watch for unwanted side effects such as burning and skin 
irritations. 
Use at other body sites is not recommended. 
Corticosteroids
Table 2 Tabular summary
Corticosteroids
First approved in
Germany
1956 (Psoriasis vulgaris)
Recommended control
parameters
None
Recommended initial
dosage
One to two times daily
Recommended
maintenance dosage
Gradual reduction following onset of effect
Expected beginning
of clinical effect
After 1–2 weeks
Response rate Betamethasone dipropionate, two times
daily: marked improvement or clearance
of the skin lesions in 46–56% patients
after 4 weeks (LE 1)
Important
contraindications
Skin infections, rosacea, perioral dermatitis
Important ADRs Skin infections, perioral dermatitis, skin
atrophy, hypertrichosis, striae
Important drug
interactions
None
Other –
General assessment 
Of the 100 studies assessed for a monotherapy with corticosteroids, 
20 fulfilled the Guidelines’ inclusion criteria.
[17-36]
With the application of potent corticosteroids (betamethasone 
dipropionate, 2× daily), 46–56% of the patients showed a clear 
improvement or a complete clearing of the skin lesions. 
Therapy with very potent corticosteroids (clobetasol-17-propionate, 
2× daily) demonstrated similar results in 68–89% of the patients in 
most studies. 
Topical corticosteroids demonstrate a good to very good efficacy in 
the treatment of mild to moderate psoriasis vulgaris (LE 1). 
The combination of topical corticosteroids with salicylic acid en-
hances the therapeutic effect. 
Combination with other systemic or topical therapies also results in 
improved rates of remission. The most common combination is with 
topical vitamin D3 derivates.  
There are no severe adverse drug reactions in the induction phase. 
Care must be taken regarding the development of typical adverse 
corticosteroid effects such as skin atrophies or teleangiectases in 
cases of longer application and in particularly sensitive areas. 
The practicality for physicians and patients is good. 
Therapeutic recommendation 
Therapy with topical corticosteroids is highly recom-
mended for mild to moderate psoriasis vulgaris as a 
combination therapy with systemic therapies or other 
topical therapies. 
The selection of the class of corticosteroids must be 
adjusted for the specific skin area to be treated.  
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123Coal tar
Table 3 Tabular summary
Coal tar
First approved in
Germany
Listed active ingredient since 2000 (DAC
on page 170), historical application,
various tar-containing externals are
licensed as drugs, application of tar as
anti-psoriatic following publication by
Goeckermann in 1925
Recommended
control parameters
After long-term application/application on
large areas: if needed clinical controls
for potential development of skin
carcinoma
Recommended initial
dosage
5–20% salve preparations or gels for local
therapy, 1· daily
Recommended
maintenance
dosage
No long-term application (max. 4 weeks,
DAC 2000)
Expected beginning
of clinical effect
After 4–8 weeks, efﬁcacy improves in
combination with UV application
Response rate There is insufﬁcient data available on the
response rate as a monotherapy (LE 4)
Important
contraindications
Pregnancy and nursing
Important ADRs Color, odor, carcinogenic risk,
phototoxicity—which is part of the
desired effect
Important drug
interactions
Not known with topical use
Other DAC 2000 (on page 170), Hazardous
Goods Directive Appendix 4 No. 13
General assessment 
Of 19 studies assessed, four fulfilled the Guidelines’ inclusion 
criteria.
[37-40] Since only one monotherapy study was evaluated (with 
three patients), it is not possible to make a clear statement about the 
efficacy of monotherapy (LE 4). 
Coal tar is used in clinical studies in combination with photother-
apy. 
In the combination therapy with UV light, a reduction of the PASI 
by about 75% was achieved in 45–80% of study participants after 
15–20 applications. The additional effect of coal tar in combination
therapy with UV compared to UV therapy alone has not been proven.
The acceptance of coal tar is low due to its color and odor. 
Magistral preparations may be less expensive than comparable 
manufactured products. 
Therapeutic recommendation 
The efficacy of coal tar treatment in psoriasis vulgaris 
has not been demonstrated, either as monotherapy or 
combination therapy. For this reason, coal tar is not 
recommended for this indication. 
In view of the low-risk and more practical therapeutic 
alternatives, a monotherapy of psoriasis vulgaris with 
coal tar is obsolete.  
Only after careful consideration of the therapeutic 
benefit and after low-risk therapeutic alternatives have 
failed should coal tar be used in combination with UVB 
in exceptional refractory cases of psoriasis vulgaris 
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Table 4 Tabular summary
Dithranol
First approved in Germany
Psoralon 1983 (Psoriasis vulgaris)
Psoradexan 1994 (Psoriasis vulgaris)
Micanol 1997 (Psoriasis vulgaris)
Recommended
control parameters
Intensity of irritation
Recommended initial
dosage
Begin with 0.5% preparation for long-term
therapy or 1% for short-contact therapy,
then increase if tolerated
Recommended
maintenance
dosage
Not recommended for maintenance therapy
Expected beginning
of clinical effect
After 2–3 weeks
Response rate Marked improvement or clearance of skin
lesions in 30–50% of the patients (LE 2)
Important
contraindications
Acute, erythrodermic forms of psoriasis
vulgaris; pustular psoriasis
Important ADRs Burning and reddening of the skin in >10%
Important drug
interactions
–
Other –
General assessment 
Of 63 studies assessed for a monotherapy with dithranol, 11 ful-
filled the Guidelines’ inclusion criteria.
[7-17]
The results of the studies assessed showed total remission (PASI 
reduction 100%) in 30–70% of the patients and partial remission 
(PASI reduction 75%) in 26–100% of patients after 5–8 weeks of 
treatment (LE 2). 
The efficacy can be increased further if either calcipotriol creams or 
a UVB phototherapy is combined with dithranol. 
Dithranol, one of the oldest topical therapeutics for psoriasis vul-
garis, is still a treatment for mild to moderate psoriasis vulgaris as 
an out-patient monotherapy and as part of combination therapies for 
moderate psoriasis vulgaris in hospitalized and day clinic patients. 
The therapy is very safe. Although skin irritations, burning, ery-
thema and intermittent brown discolorations are observed, there are 
no systemic adverse drug reactions. 
The practicality is clearly limited for outpatient use. The practicality 
for the physician, especially when treating inpatients, and the cost-
benefit ratio are positive. 
Therapeutic recommendation 
Monotherapy for patients with mild and moderate psoria-
sis vulgaris is recommended for induction therapy during 
hospitalization  
And conditionally recommended as an outpatient treat-
ment. 
Because it is more practical, short-contact therapy should 
be given preference. In hospitalized patients, classical 
dithranol therapy with 2× daily application without 
immediate rinsing can be easily performed. 
The therapy should be performed for 4 and conditionally 
recommended as an outpatient treatment for 4–8 weeks. 
Maintenance or long-term therapy with dithranol is not 
practical and offers no advantages. 
In the treatment of severe forms of psoriasis vulgaris, 
combination treatment with phototherapy or other topical 
preparations (calcipotriol) is recommended because of 
the improved response rate.  
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Table 5 Tabular summary
Tazarotene
First approved in
Germany
1997 (psoriasis vulgaris)
Recommended
control parameters
Check development of skin irritations
Recommended initial
dosage
Begin with one treatment daily of
tazarotene gel 0.05% in the evening for
approximately 1–2 weeks
Recommended
maintenance
dosage
If necessary continue for 1–2 weeks with
tazarotene gel 0.1%
Expected beginning
of clinical effect
After 1–2 weeks
Response rate After 12 weeks therapy with 0.1%
tazarotene gel improved ﬁndings of at
least 50% in approximately 50% of the
patients (LE 2)
Important
contraindications
Pregnancy, nursing
Important ADRs Pruritus, burning sensation of skin,
erythema, irritation
Important drug
interactions
Avoid concomitant use of preparations
with irritating and drying properties
Other –
General assessment  
Of the nine studies assessed, six fulfilled the Guidelines’ inclusion 
criteria.
[41-46]
After daily treatment with tazarotene 0.1%, approximately 50% of 
the patients showed at least a 50% improvement of the skin lesions 
after about 12 weeks of treatment (LE 2). 
An optimization of the therapeutic success and a reduction of the 
frequent skin irritations can be attained with a combination of 
tazarotene and topical corticosteroids. 
There are no severe adverse drug reactions. However, contact with 
healthy skin should be avoided to prevent skin irritation. 
Therapeutic recommendation 
The topical application of tazarotene is recommended for 
the treatment of mild to moderate psoriasis vulgaris. 
An application of tazarotene in the evening in combina-
tion with a corticosteroid in the morning is recommended 
as a combination therapy to reduce irritation and increase 
efficacy. 
Vitamin D3 and analogues
Table 6 Tabular summary
Vitamin D3 and analogues
First approved in Germany
Calcipotriol 1992 (Psoriasis vulgaris)
Tacalcitol 1994 (Psoriasis vulgaris)
Calcitriol 1999 (Psoriasis vulgaris)
Calcipotriol/
Betamethasone
2002 (Psoriasis vulgaris)
Recommended
control parameters
Monitor for skin irritations
Recommended initial
dosage
Calcipotriol: 1· to 2· daily to affected
locations, up to a maximum of 30% of
the body surface
Tacalcitol: 1· daily to affected locations,
up to a maximum of 20% of the body
surface
Calcitriol: 2· daily to affected locations, up
to a maximum of 35% of the body
surface
Recommended
maintenance
dosage
Calcipotriol: 1· to 2· daily, up to 100 g/
week for up to 1 year
Tacalcitol: 1· daily for 8 weeks, for up to
18 months, on a maximum of 15% of the
body surface with up to 3.5 g daily
Calcitriol: insufﬁcient experience with the
application for more than 6 weeks
Expected beginning
of clinical effect
After 1–2 weeks
Response rate Between 30 and 50% of the patients
demonstrated a marked improvement or
clearance of the lesions after 4–6 weeks
(LE 1)
Important
contraindications
Diseases with abnormal calcium
metabolism, severe liver and renal
diseases
Important ADRs Skin irritation (reddening, itching, burning)
Important drug
interactions
Drugs which elevate the calcium levels,
(e.g. thiazide diuretics), no
concomitant application of topical
salicylic acid preparations
(inactivation)
Other Exposure to UV light results
in inactivation of the vitamin
D3-analogues
Arch Dermatol Res (2007) 299:111–138 119
123General assessment 
Of the 39 studies considered, 11 fulfilled the Guidelines’ inclusion 
criteria.
[14, 22-25, 47-52]
The majority of available data is on calcipotriol. After vitamin D3-
analogue treatment of mild to moderate psoriasis vulgaris, 30–50% 
of the patients showed a marked improvement or clearance of the 
skin lesions within a few weeks (LE 1). 
The efficacy and tolerance can be further improved if the Vitamin 
D3-analogue is combined with topical corticosteroids during the 
initial therapy. 
In the treatment of severely affected patients, topical therapy with 
vitamin D3-analogues demonstrated synergistic effects with a UV 
phototherapy and systemic cyclosporine therapy. 
The topical vitamin D3-analogues are generally well-tolerated and 
practicable for the physician and the patient. Temporary skin irrita-
tions may limit the use, especially on the face or the intertriginous 
areas. 
Therapeutic recommendation 
Vitamin D3-analogues are the treatment of choice, espe-
cially for maintenance therapy in mild to moderate 
psoriasis vulgaris. 
On the basis of the extensive study data and the superior 
efficacy, this recommendation is particularly true for 
calcipotriol. Because of its low irritating potential, the 
application of tacalcitol is particularly recommended for 
sensitive areas (e.g. face). 
In the first weeks, use together with topical corticoster-
oids or as a fixed combination is superior to monother-
apy with respect to efficacy and tolerance. 
For moderate to severe psoriasis vulgaris, a combination 
of topical vitamin D3-analogues with UV phototherapy or 
a systemic therapy can be recommended. 
Phototherapy
Table 7 Tabular summary
Phototherapy
First approved in
Germany
Clinical experience, depending on the
modality for >50 years
Recommended
control parameters
Regular skin inspection (UV erythema)
Recommended initial
dosage
Individual dose depends on skin type;
options:
• UVB: 70% of minimum erythema dose
(MED)
• Oral PUVA (photochemotherapy): 75%
of the minimum phototoxic dose (MPD)
• Bath/cream PUVA: 20–30% of MPD
Recommended
maintenance
dosage
Increase according to degree of UV
erythema
Expected beginning
of clinical effect
After 1–2 weeks
Response rate In >75% of the patients PASI,
75 after 4–6 weeks (LE 2)
Important
contraindications
Photo-dermatoses/photosensitive diseases,
skin malignancies, immunosuppression
Only PUVA: pregnancy and nursing
Important ADRs Erythema, itching, blistering, malignancies
Only oral PUVA: nausea
Important drug
interactions
Drugs causing phototoxicity or
photoallergy
Other Combination with topical preparations acts
synergistically, PUVA may not be
combined with cyclosporine
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Instructions for application 
 
Pre-treatment 
 
The attending physician has to perform a complete skin exami-
nation, paying special attention to melanocytic nevi (especially 
if dysplastic) and cutaneous malignancies. 
The patient has to be informed about unwanted side effects and 
possible long-term risks – especially the therapy-related in-
creased risk of skin cancer. Additional UV exposure as a result 
of leisure-time activities should be considered. Written in-
formed consent must be obtained. 
Before starting oral PUVA therapy, an ophthalmologic exami-
nation and the prescription of UV sunglasses is required. 
 
During treatment 
 
The UV dosages applied must be documented in precise physi-
cal units (J/cm
2 or mJ/cm
2). 
Regular monitoring of UV erythema must be performed for 
the purpose of dosage increase. 
The medical records should document therapeutic response, 
unwanted side effects, and accompanying treatments.  
Eye protection with UV glasses is generally required. 
If the areas chronically exposed to light (face, neck, backs of 
hands) and the genital region are free of lesions, these should 
be protected from exposure. 
Adequate protection from the sun must accompany therapy. 
 
Post-treatment 
 
Whenever a course of therapy is completed, the cumulative 
UV dosage and the number of treatments should be recorded 
and the patient has to be informed.  
Particularly in the case of patients with high cumulative UV 
dosage, a regular skin cancer examination should be per-
formed for the patient’s entire life. 
 
 
 
 
General assessment 
 
Of the 145 studies on monotherapy or combination therapy as-
sessed, 25 studies on phototherapy, 32 studies on PUVA therapy, 
and five studies on therapeutic procedures with lasers fulfilled the 
Guidelines’ inclusion criteria.
[37-40, 53-100] 
About three-quarters of all the patients treated with phototherapy 
attained at least a 75% PASI score reduction after 4–6 weeks, and 
clearance was frequently achieved (LE 2). 
Phototherapy represents a safe and very effective modality for the 
treatment of moderate to severe forms of psoriasis vulgaris. The 
onset of the clinical effects is within 2 weeks. 
Of the unwanted side effects, UV erythema from overexposure is by 
far the most common and is observed frequently. With repeated or 
long-term application, the consequences of high, cumulative UV 
dosages (i.e. premature aging of the skin) must be taken into con-
sideration. In addition, carcinogenic risk is associated with oral 
PUVA and is probable for local PUVA and UVB. 
The practicality of the therapy is limited as a result of the spatial, 
financial, and human aspects as well as by time resources on the 
part of the physician as well as the amount of time required by the 
patient. 
From the perspective of the cost-bearing institution, phototherapy 
has a good cost-benefit ratio. However, the potentially significant 
costs and time required of the patient must be noted. 
 
 
 
Therapeutic recommendation 
Phototherapy is recommended as an induction therapy 
for moderate to severe psoriasis vulgaris, above all for 
widespread involvement. 
The side effects of specific types of radiation must be 
weighed. A possible subsequent risk of skin cancer is 
better documented for PUVA than for UVB. 
Due to its low practicality and the association of long-
term unwanted side effects with the cumulative UV 
doses, phototherapy is not suitable for long-term treat-
ment. 
Combination with topical vitamin D3-analogues is rec-
ommended to improve the response rate.
A recommendation for the common combination with 
dithranol and corticosteroids can only be given on the 
basis of clinical experience, but not on the basis of 
scientific data. 
The use of Excimer Lasers should be limited to the 
targeted treatment of individual psoriatic plaques. 
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Efalizumab
Table 8 Tabular summary
Efalizumab
First approved in
Germany
September 2004 (psoriasis vulgaris)
Recommended control
parameters
Prior to therapy exclusion of signiﬁcant
infections, complete blood count,
liver values
Recommended initial
dosage
0.7 mg/kg body weight (BW) per week
Recommended
maintenance dosage
1 mg/kg BW per week
Expected beginning
of clinical effect
After 4–8 weeks
Response rate PASI 75 for approximately 30% of the
patients after 12 weeks (LE 1)
Important
contraindications
(limited selection)
Chronic or acute infections, pregnancy,
malignant diseases, immune
deﬁciencies, no vaccinations before
or during treatment
Important ADRs (limited
selection)
Flu-like injection reactions,
leukocytosis and lymphocytosis,
rebound, exacerbation and
arthralgia, thrombocytopenia
Important drug
interactions
Not known
Other Stop therapy due to the risk of
exacerbation and rebound if a PASI
reduction of 50% is not achieved
after 12 weeks
 
 
Instructions for application 
 
Pre-treatment 
 
Exclusion of severe systemic (acute and chronic) and local 
infections (e.g. abscesses) 
Reliable contraception and exclusion of pregnancy in women 
of childbearing age 
Patients should be made aware of the risks of and be moni-
tored for severe infections  
Laboratory controls (see Table 3.5.1.1.2) 
 
During treatment 
Exclusion of infections; the therapy should at least be tempo-
rarily discontinued when there is a suspicion of such. 
After 12 weeks of treatment, assessment of the therapeutic 
success: in case of good results (PASI > 50% improvement), 
treatment with efalizumab can be continued; otherwise, the 
treatment should be discontinued. 
In case of an exacerbation, another suitable psoriasis therapy 
should be introduced. In this case, other biologics should be 
considered. 
Laboratory controls (see Table 3.5.1.1.2) 
 
Post-treatment  
Patients, who discontinue efalizumab should be subject to 
close follow-up. 
In cases of reoccurrence or exacerbation of the disease, the 
introduction of another suitable psoriasis treatment is recom-
mended. 
Patients should be informed about the possibility of the occur-
rence of a rebound, which would make an immediate consulta-
tion necessary. 
 
Table 9 Laboratory controls during treatment with efalizumab
--------------------------------------------------------------------------------------------------------------------------- 
Complete blood count
a  x  x x x x x x x 
--------------------------------------------------------------------------------------------------------------------------- 
ALT, AST
b  x      x 
Period in months 
Diagnostics       Before  1 2 3 4 5 6 9 
a Hb (hemoglobin), HCT (hematocrit), erythrocytes, leukocytes, differential blood count,
platelets
b ALT alanine aminotransferase, AST aspartate aminotransferase
122 Arch Dermatol Res (2007) 299:111–138
123General assessment 
All six of the studies assessed in terms of the efficacy of therapy 
with efalizumab fulfilled the Guidelines’ inclusion criteria.
[101-106]
Approximately 30 and 40% of those patients with moderate to 
severe psoriasis vulgaris treated with efalizumab at a dose of 1 
mg/kg BW per week attained a PASI reduction of > 75% (LE 1) 
within 12 weeks and 24 weeks, respectively. 
As a result of the only once-per-week subcutaneous injection and 
the only rarely required medical controls, the therapy is highly 
practicable for both the patient and the attending physician. 
Based on current knowledge, efalizumab possesses a favorable 
safety profile. 
A follow-up of a larger patient population for a longer period of 
time is necessary for a definitive assessment of the efficacy and 
safety as a long-term treatment. 
Compared to other biologics, experience with efalizumab is signifi-
cantly lower due to the smaller patient populations which have been 
treated with efalizumab. 
Disease exacerbation during therapy or a rebound after therapy has 
been observed. 
Therapeutic recommendation 
Efalizumab is recommended for induction therapy of 
moderate to severe psoriasis vulgaris especially if other 
therapeutic options have not demonstrated sufficient 
therapeutic effect, are not tolerated, or are contraindi-
cated. 
Therapy should not be continued if an improvement of at 
least 50% of the initial findings is not observed after the 
first 12 weeks of treatment. 
Etanercept
Table 10 Tabular summary
Etanercept
First approved in
Germany
2002 (Psoriasis arthritis )/2004
(psoriasis vulgaris)
Recommended control
parameters
Prior to therapy exclusion of
tuberculosis, complete blood count,
liver and renal values, urinanalysis
Recommended initial
dosage
Twice 25 mg per week or 2· 50 mg/
week
Recommended
maintenance dosage
Twice 25 mg per week
Expected beginning
of clinical effect
After 4–8 weeks, at the latest after
12 weeks
Response rate PASI 75 in 34% (2 · 25 mg) or 49%
(2 · 50 mg) of the patients at the
end of the induction phase
(12 weeks) (LE 1)
Important
contraindications
(limited selection)
Infections, pregnancy, nursing, heart
failure NYHA III–IV
Important ADRs (limited
selection)
Local reactions, infections
Important drug
interactions (limited
selection)
Anakinra (IL-1 receptor antagonist)
Other –
 
 
Instructions for application 
 
Pre-treatment 
 
Exclusion of acute and chronic infections. An absolute exclu-
sion of tuberculosis in accordance with the recommendations 
by the Paul Ehrlich Institute (www.pei.de) 
Reliable contraception and exclusion of pregnancy for women 
of child-bearing age 
Patients should be made aware of the risk of severe infections 
 
During treatment 
 
At each visit, presence of infections should be excluded; the 
therapy should, at least temporarily, be discontinued in suspi-
cious cases 
Monitoring for infections 
Etanercept therapy should be terminated or temporarily dis-
continued if there are signs of severe infection 
Discontinuation of therapy in case of onset of pregnancy 
Continued treatment with etanercept after 12 weeks if response 
is good, otherwise therapy should be discontinued 
 
Post-treatment 
 
None 
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Table 12 Tabular summary
Inﬂiximab
First approved
in Germany
2004 (Psoriasis arthritis)/2005
(psoriasis vulgaris)
Recommended control
parameters
Prior to therapy exclusion of
tuberculosis, during therapy:
leukocyte and platelet counts, liver
value controls, signs of clinical
infection
Recommended initial
dosage
5 mg/kg BW at week 0, 2, 6
Recommended
maintenance dosage
5 mg/kg BW in dosage intervals of
8 weeks
Expected beginning
of clinical effect
After 1–2 weeks
Response rate PASI 75 in ‡80% of the patients with
moderate to severe psoriasis vulgaris
(LE 1)
Important
contraindications
(limited selection)
Acute or chronic infections,
tuberculosis, cardiac failure NYHA
III–IV, pregnancy and nursing
Important ADRs (limited
selection)
Infusion reactions, severe infections,
progression of heart failure NYHA
III–IV, very rare liver failure,
autoimmune phenomena
Important drug
interactions (limited
selection)
Anakinra (IL-1 receptor antagonist)
Other –
 
 
Instructions for application 
 
Pre-treatment 
 
Exclusion of acute and chronic infections, absolute exclusion 
of tuberculosis in accordance with the current recommenda-
tions of the Paul Ehrlich Institute (www.pei.de) 
Reliable contraception and exclusion of pregnancy in women 
of childbearing age  
Patients should be informed about the risk of severe infections. 
Hand out user information and special comment card to pa-
tients 
 
During treatment 
 
Monitoring during infusion and 1–2 hours thereafter 
Monitoring for infections; the therapy should at least be tem-
porarily discontinued when an infection is suspected 
 
Post-treatment 
 
In women of childbearing age, contraception for up to 6 
months after infliximab therapy 
 
 
Table 11 Laboratory controls during treatment with etanercept
Period in months 
Diagnostics    before   1   3   6   8 
--------------------------------------------------------------------------------------------------------------------------- 
Diff. Blood count  x   x   x   x   x 
--------------------------------------------------------------------------------------------------------------------------- 
ALT, AST  x   x   x   x   x 
--------------------------------------------------------------------------------------------------------------------------- 
Pregnancy test x 
(urine) 
General assessment 
Of the four studies assessed, three fulfill the Guidelines’ inclusion 
criteria.
[107-109]
During etanercept therapy, approximately 35% of the patients 
attained a PASI reduction of 75% after 12 weeks with two subcuta-
neous doses of  25 mg per week. With a therapy with 2× 50 mg 
subcutaneous per week for 12 weeks approximately 50% of the 
patients attained a PASI reduction of 75% (LE 1). 
Clinical experience has shown that clinical efficacy can be main-
tained in a long-term therapy for up to 24 weeks.  
The therapy is practicable for both the patient and the physician. 
As a result of the large number of patients treated with etanercept 
for other indications, the risk of adverse drug reactions can be 
estimated very well. 
Therapeutic recommendation 
Etanercept is recommended for induction therapy for 
patients with moderate to severe psoriasis vulgaris, 
especially if other therapeutic options have not demon-
strated satisfactory therapeutic success, are not toler-
ated, or are contraindicated. 
If concomitant psoriasis vulgaris and relevant psoriasis 
arthritis are present, treatment with TNF-alpha antago-
nists is particularly recommended. 
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Table 14 Tabular summary
Cyclosporine
First approved
in Germany
1983 (Transplantation medicine)
1993 (Psoriasis vulgaris)
Recommended control
parameters
Interview/examination:
• Status of skin and mucous
membranes
• Signs of infection
• Neurological, gastrointestinal
symptoms
• Blood pressure
Laboratory controls: see Table 14
Recommended initial
dosage
2.5–3 (max. 5) mg/kg BW
Recommended
maintenance dosage
Interval therapy (between 8 and 16
weeks) with dosage reduction at the
end of the induction therapy (e.g.,
0.5 mg/kg BW every 14 days) or
Continuous long-term therapy with
dosage reduction (e.g. by 50 mg
every 4 weeks after week 12) and a
dosage increase by 50 mg with
relapse
Maximum total duration of therapy:
2 years
Expected beginning
of clinical effect
After approximately 4 weeks
Response rate Dose-dependent: after 8–16 weeks
with 3 mg/kg BW; PASI 90 in
approximately 30–50% of patient
and PASI 75 in approximately 50–
70% of patients (LE 1)
Important
contraindications
(limited selection)
Absolute:
Reduced renal function, insufﬁciently
controlled arterial hypertension,
uncontrolled infections, relevant
malignancies (current or previous, in
particular hematologic diseases and
cutaneous malignancies with the
exception of basal cell carcinoma)
Relative:
Relevant hepatic dysfunction,
pregnancy and nursing, concomitant
use of substance which interacts with
cyclosporine, concomitant UV-
therapy or prior PUVA-pre-therapy
with cumulative dosage >1000 J/
cm2, concomitant application of
other immunosuppressives, retinoids
or long-term prior-therapy with
methotrexate (MTX)
General assessment 
Of the seven studies evaluated, four fulfill the Guidelines’ inclusion 
criteria.
[110-113]
Approximately 88% of the patients with moderate to severe psoria-
sis showed a PASI reduction of 75% after 10 weeks infliximab 
treatment with a dose of 5 mg/kg BW in the normal therapy inter-
vals (LE 1). 
Infliximab is currently one of the most effective drugs for the treat-
ment of psoriasis vulgaris. On the basis of the data available from 
long-term studies, good efficacy is also expected in the long-term 
therapy of psoriasis vulgaris. 
A number of safety aspects should be considered with infliximab. 
Amongst these are, above all, infusion reactions and the risk of 
severe infection. This requires a careful evaluation of the indication, 
education, as well as monitoring of the patient. 
As a result of the large number of patients treated with infliximab 
for other indications, the risk of adverse drug reactions can be 
estimated very well. 
Therapeutic recommendation 
Infliximab is recommended for the induction therapy of 
moderate to severe psoriasis vulgaris and severe, special 
forms of psoriasis which cannot be controlled by other 
therapeutic options or if, on the basis of the severity of 
the disease, a rapid resolution is required. 
If concomitant psoriasis vulgaris and relevant psoriasis 
arthritis are present, treatment with TNF-alpha antago-
nists is particularly recommended. 
Table 13 Laboratory controls during treatment with inﬂiximab
Period in months
Diagnostics   Before   1   2   3 
---------------------------------------------------------------------------------------------------------------------------
Complete blood count
a x  Prior  to  start of therapy and before every infusion 
--------------------------------------------------------------------------------------------------------------------------- 
AST, ALT  x  Prior to start of therapy and before every infusion 
--------------------------------------------------------------------------------------------------------------------------- 
Pregnancy test (urine) x 
aHb, HCT, erythrocytes, leukocytes, differential blood count, platelets
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Cyclosporine
Important ADRs (limited
selection)
Renal failure, increase of blood
pressure, liver failure, nausea,
anorexia, vomiting, diarrhea,
hypertrichosis, gingival hyperplasia,
tremor, weariness, parasthesia,
hyperlipidemia
Important drug
interactions (limited
selection)
Increase of the cyclosporine level
(CYP3A inhibition) through:
Allopurinol, calcium antagonists,
amiodarone, antibiotics (macrolides,
clarithromycin, josamycin,
ponsinomycin, pristinamycin,
doxycycline, gentamicin,
tobramycin, ticarcillin, quinolones),
ketoconazole, oral contraceptives,
methylprednisolone (high dosages),
ranitidine, cimetidine, grapefruit
juice
Decrease of the cyclosporine level
(CYP3A induction) through:
Carbamazepine, phenytoin,
barbiturates, metamizole, St. John’s
wort
Possible reinforcement of nephrotoxic
adverse drug reactions through:
Aminoglycosides, amphotericin B,
ciproﬂoxacin, acyclovir, non-
steroidal antiphlogistics
Speciﬁc interactions:
Potassium-saving substances: increased
risk of hyperpotassemia
Reduced clearance of: Digoxin,
colchicine, prednisolone, HMG-CoA
reductase inhibitors (e.g. lovastatin),
diclofenac
Other Increased risk of lympho-proliferative
diseases in transplant patients.
Increased risk of squamous cell
carcinoma in psoriasis patients
following excessive phototherapy.
Only moderately effective in and not
approved for psoriatic arthritis
Also used successfully in the therapy of
chronic-inﬂammatory diseases in
children
 
 
 
Instructions for application 
 
Pre-treatment 
 
History 
Previous and concomitant diseases (e.g. severe infections, 
malignancies, renal and liver diseases), concomitant medica-
tions (see Drug Reactions) 
 
Questions/examination 
Examination for skin malignancies  
Indications of existing infections 
Measurement of the blood pressure at two different times 
 
Laboratory controls (see Table 3.5.2.2) 
 
Consultation 
Reliable contraception (cave: reduced efficacy of progester-
one-containing contraceptives) 
Vaccination, susceptibility to infections [take infections seri-
ously and, if needed, early presentation (e.g., visit GP)] 
Drug interactions (inform other treating physicians about 
therapy) 
Avoid excessive sun exposure, use of light-protection meas-
ures 
 
Measures during the therapy 
 
Questions/examination 
Status of skin and mucous membranes (e.g., increase of body 
hair, gingival hyperplasia) 
Signs of infections 
Gastrointestinal or neurological symptoms 
Repeat recommendation for light avoidance and protection 
from sun light 
Check concomitant medications 
Measure blood pressure 
 
Laboratory controls (see Table 3.5.2.2) 
With an uncomplicated long-term therapy with low dose (2.5–
3 mg/kg BW daily) control intervals may later be extended to 
2 months  
Short intervals (e.g., in patients with risk factors), dosage 
increases with the intake of metabolic drugs or with regard to 
the ADRs of interacting drugs 
Creatinine clearance in cases of implausible creatinine plasma 
levels 
In selected patients with intermittent and short-term treatment, 
a smaller number of controls (e.g., regular controls of blood 
pressure and creatinine assay) may be sufficient 
Determination of the cyclosporine level is recommended in 
individual cases 
 
Measures after therapy 
 
None 
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Table 16 Tabular summary
Fumaric acid esters
First approved in
Germany
1995 (Psoriasis vulgaris)
Recommended control
parameters
Serum creatinine, transaminases/cGT,
complete blood count including
differential blood count, urinanalysis
Recommended initial
dosage
According to recommended dosage
regimen see Table 17
Recommended
maintenance dosage
Individually adapted dosage
Expected beginning of
clinical effect
After approximately 6 weeks
Response rate PASI 75 in 50–70% of the patients at
the end of the induction phase after
16 weeks (LE 2)
Important
contraindications
(limited selection)
Chronic diseases of the gastrointestinal
tract and/or the kidneys and chronic
diseases, which are accompanied by
an impairment of the leukocyte
count or functions, malignant
diseases, pregnancy and nursing
Important ADRs (limited
selection)
Gastrointestinal complaints, ﬂush,
lymphopenia, eosinophilia
Important drug
interactions
None known
Other –
Table 17 Dosage regimen for Fumaderm therapy
Fumaderm initial Fumaderm
Week 1 1-0-0
Week 2 1-0-1
Week 3 1-1-1
Week 4 1-0-0
Week 5 1-0-1
Week 6 1-1-1
Week 7 2-1-1
Week 8 2-1-2
Week 9 2-2-2
General assessment 
Of 65 studies evaluated with respect to the efficacy of a cyc-
losporine monotherapy in psoriasis, 15 studies fulfilled the Guide-
lines’ inclusion criteria.
[86, 114-127] Cyclosporine demonstrated a high 
effectiveness in the therapy of adults in these clinical studies. After 
12–16 weeks, 50–70% of the patients achieved a PASI 75 (LE 1). 
Cyclosporine is primarily suited for induction therapy; in long-term 
therapy a careful and individual weighing of the risks and benefits 
must be performed due to the adverse drug reactions, especially the 
nephrotoxicity and increase in blood pressure as well as the possi-
bility of an increased risk of malignancies. 
With the application of cyclosporine, a variety of drug reactions 
need to be considered, which on the one hand lead to a change in 
the availability of cyclosporine or concomitant medications, and on 
the other hand might increase the risk of adverse drug reactions. 
As a result of its long-term use for various indications, including 
psoriasis vulgaris, an extensive body of data is available – also in 
terms of safety during long-term therapy with cyclosporine. 
Cyclosporine represents an effective therapy for moderate and 
severe psoriasis vulgaris. 
Therapeutic recommendation 
Cyclosporine is primarily recommended for induction 
therapy for moderate to severe psoriasis vulgaris in adults 
who cannot be sufficiently treated with a topical therapy 
and/or phototherapy. In these cases, there is an accept-
able risk-benefit ratio. 
Cyclosporine can also be used for the long-term therapy 
of suitable patients over a period of up to 2 years maxi-
mum, whereby an increasing toxicity and a decreasing 
efficacy should be considered. 
A combination with topical preparations for the treatment 
of psoriasis vulgaris is possible and reasonable, espe-
cially because there are signs that combining cyc-
losporine with topical vitamin D3-analogues or corticos-
teroids may allow a dose reduction of cyclosporine 
without a loss of efficacy. 
Table 15 Laboratory controls during treatment with cyclosporine
Period in weeks 
Diagnostics
------------------------------------------------------------------------------------------------------------------------------------ 
Complete blood count
a  x  x   x   x   x   x 
------------------------------------------------------------------------------------------------------------------------------------ 
Liver values
b    x  x   x   x   x   x 
----------------------------------------------------------------------------------------------------------------------------------- 
Electrolytes
c    x  x    x   x   x   x 
----------------------------------------------------------------------------------------------------------------------------------- 
Serum creatinine   x  x    x    x    x    x 
----------------------------------------------------------------------------------------------------------------------------------- 
Urea    x  x   x   x   x   x 
----------------------------------------------------------------------------------------------------------------------------------- 
Urinanalysis and 
-sediment    x    x   x   x   x 
----------------------------------------------------------------------------------------------------------------------------------- 
Uric acid   x  x    x    x    x 
----------------------------------------------------------------------------------------------------------------------------------- 
Pregnancy test 
(urine)   x 
----------------------------------------------------------------------------------------------------------------------------------- 
Cholesterol, 
triglycerides
d    x      x     x 
----------------------------------------------------------------------------------------------------------------------------------- 
Magnesium
e x
         x  x  
Before 2 4 8 12 16
a Erythrocytes, leukocytes, platelets
b ALT, AST, AP (alkaline phosphatase), cGT (gamma glutamyl transpeptidase), bilirubin
c Sodium, potassium
d Recommended twice (fasting) and week-2 and 0
e Only with indication (e.g. muscle cramps)
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Instructions for application 
 
Pre-treatment 
 
Laboratory controls (see Table 3.5.3.3) 
 
During treatment  
 
Laboratory controls (see Table 3.5.3.3) 
 
Post-treatment 
 
None 
 
 
General assessment 
Of 13 studies evaluated, nine fulfilled the Guidelines’ inclusion 
criteria.
[128-136] After 16 weeks, 50–70% of the patients had a PASI 75 
(LE 2). 
There was good efficacy in the induction therapy and in the long-
term therapy. 
The therapy of psoriasis vulgaris with fumaric acid esters represents 
an effective systemic treatment which demonstrates a high level of 
long-term safety. 
The tolerance is limited by adverse gastrointestinal drug reactions 
and flush symptoms. 
The risk-benefit analysis of fumaric acid esters is positive, the 
practicality for both patients and physicians is good, and the cost-
benefit ratio is acceptable. 
Positive aspects of the therapy with fumaric acid esters are the low 
number of drug interactions, the lack of immunosuppressive effects, 
the absence of increased susceptibility to infection, and the absence 
of any risk of malignancies during the long-term therapy. 
A combination with topical medications for the treatment of psoria-
sis vulgaris is recommendable.  
Therapeutic recommendation 
Treatment with fumaric acid esters is recommended as 
an effective induction therapy for moderate to severe 
psoriasis vulgaris in adults. 
Their application is primarily limited by gastrointestinal 
ADRs. A combination with any topical drugs for the 
treatment of psoriasis vulgaris is possible and reason-
able. 
Because of the favorable risk-benefit profile with good 
tolerability during long-term therapy, fumaric acid 
esters are highly recommended. 
Table 18 Laboratory controls during treatment with fumaric acid
esters
Period in weeks   Pre-treatment  Month  1–6 After  month  6 
Diagnostics       every 4 weeks  every 8 weeks 
-------------------------------------------------------------------------------------------------------------------------------
Complete blood count
a x  x  x 
--------------------------------------------------------------------------------------------------------------------------- 
ALT, AST,γ   GT     x  x  x 
--------------------------------------------------------------------------------------------------------------------------- 
Serum creatinine   x  x  x 
--------------------------------------------------------------------------------------------------------------------------- 
Urinanalysis   x  x  x 
a Leukocytes, platelets, erythrocytes, differential blood count
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Table 19 Tabular summary
Methotrexate
First approved in Germany
Lantarel
  1991 (Psoriasis vulgaris)
Metex
  7.5/10 mg 1992 (Psoriasis vulgaris)
Metex
  2.5 mg 2004 (Psoriasis vulgaris)
Recommended control
parameters
Complete blood count (Hb, HCT,
differential blood count, platelets),
renal function (serum creatinine,
urea, urine sediment), liver values
(serum transaminases), III-
procollagen amino terminal
propeptides
Recommended initial
dosage
5–15 mg per week
Recommended
maintenance dosage
5–22.5 mg per week depending on
effect
Expected beginning
of clinical effect
After 4–8 weeks
Response rate PASI 75 in approximately 60% of the
patients at the end of the induction
phase of 16 weeks (LE 3)
Important
contraindications
(limited selection)
Absolute contraindications:
Desire to have children (for both men
and women), pregnancy and nursing,
inadequate contraception, drug
consumption, alcoholism, known
sensitivity to active ingredient
methotrexate (e.g. pulmonary
toxicity), bone marrow dysfunction,
severe liver disease, severe
infections, immunodeﬁciency, active
peptic ulcers, hematologic changes
(leucopenia, thrombocytopenia,
anemia), renal failure
Relative contraindications:
Kidney disorders, liver disorders,
history of arsenic consumption ,
chronic congestive cardio-myopathy,
adiposity, old age, diabetes mellitus,
history of hepatitis, lack of patient
compliance, ulcerative colitis,
diarrhea, NSAID use, gastritis
Important ADRs (limited
selection)
Liver ﬁbrosis/cirrhosis, pneumonia/
alveolitis, bone marrow depression,
renal damage, alopecia (reversible),
nausea, weariness, vomiting,
elevated transaminases, infection,
gastrointestinal ulcerations,
nephrotoxicity
Table 19 continued
Methotrexate
Important drug
interactions (limited
selection)
Cyclosporine, salicylates,
sulfonamides, probenecide,
penicillin, colchicin, NSAIDs
(naproxene, ibuprofene, etc.),
ethanol, co-trimoxazole,
pyrimethamine, chloramphenicol,
sulfonamides, prostaglandin
synthesis inhibitors, cytostatics,
probenecide, barbiturates, phenytoin,
retinoids, sulfonamides,
sulfonylurea, tetracyclines, co-
trimoxazol, chloramphenicol,
dipyridamole, retinoids, ethanol,
leﬂunomide
Other Consistent avoidance of alcohol, X-ray
of the lungs prior to beginning
therapy
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Instructions for application 
 
Pre-treatment 
 
Anamnesis 
Exclusion of alcohol abuse 
Physical examination 
Sonography of liver following indication, i.e., with a positive 
anamnesis or pathological findings in the physical examination 
Examine for skin signs of chronic hepatic disease 
 
Laboratory controls (see Table 3.5.4.2) 
An assay of the type III procollagen amino terminal propeptide 
(PIIINP) in serum is recommended 
 
Imaging procedures 
Chest x-ray (as necessary comparative image for the occur-
rence of pulmonary changes) 
 
Other 
Information about intake (only on 1 day a week) and early 
symptoms of potential ADRs 
 
During treatment  
 
Adequate contraceptive measures (for the treatment of both 
men and women) 
Laboratory controls (see Table 3.5.4.2) 
With dosage increases and an increased risk of an elevated 
MTX concentration (dehydration, reduced renal function, new 
medications) controls are performed more frequently 
An assay of type III procollagen amino terminal propeptide 
(PIIINP) in serum is recommended 
Liver biopsy: as soon as there is a longer treatment period 
following a cumulative dose of more than 1.5 g or more or if 
liver damage is suspected, a hepatologist should be consulted 
to determine whether a liver biopsy is needed
[73, 76] 
Chest x-ray: for complaints such as fever, coughing, dyspnoea, 
and cyanosis; important: MTX pneumonitis 
For the general reduction of toxicity, 5 mg per day folic acid 
can be recommended on the days when there is no MTX in-
take  
Careful registration of cumulative dose 
 
Post-treatment 
 
Reliable contraceptive measures for at least 3 months after 
therapy in both men and women 
 
 
General assessment 
Of 11 MTX monotherapy studies assessed for efficacy in psoriasis 
vulgaris, three studies fulfilled the Guidelines’ inclusion criteria.
[123, 
138, 139].
After a 16-week therapy with MTX, approximately 60–75% of the 
patients displayed a 75% reduction of the PASI score (LE 3). 
Clinical experience with MTX is much greater than the documenta-
tion of the efficacy and safety of a MTX therapy in clinical studies. 
Clinical experience has demonstrated that with longer treatment, the 
efficacy continues to increase and MTX therefore represents, above 
all, an effective therapeutic option for long-term therapy. 
The clinical application is restricted by severe ADRs including, in 
particular, hepatotoxicity, nephrotoxicity, bone marrow suppres-
sion, gastrointestinal ulcerations and very rare, but severe idiosyn-
cratic reactions. 
With precise patient selection, thorough patient information, strict 
monitoring, administration of the lowest effective dosage (max. 
22.5 mg per week) and the additional administration of folic acid or 
folinic acid, an acceptable safety profile can also be attained for 
MTX therapy. 
MTX provides the lowest drug costs per day of all the systemic 
therapeutics. 
Therapeutic recommendation 
MTX is effective in the treatment of moderate to severe 
psoriasis vulgaris; its use is limited by the contraindica-
tions and numerous controls needed during therapy.  
MTX is, as a result of its slow onset of action, less rec-
ommendable for short-term induction therapy than for 
long-term therapy. 
Table 20 Laboratory controls during treatment with MTX [137]
Period in weeks     Before   First month:  2nd – 3rd month  After 4th month 
Diagnostics  treatment  1×/week    1×/2  weeks    every  2–3 months 
--------------------------------------------------------------------------------------------------------------------------- 
Complete blood count
a x  x  x  x 
--------------------------------------------------------------------------------------------------------------------------- 
Liver values
b x  x  x  x 
--------------------------------------------------------------------------------------------------------------------------- 
Creatinine/urea x  x  x x 
--------------------------------------------------------------------------------------------------------------------------- 
Urine sediment x  x  x x 
--------------------------------------------------------------------------------------------------------------------------- 
Pregnancy test (urine) x 
--------------------------------------------------------------------------------------------------------------------------- 
Liver sonography
c x 
--------------------------------------------------------------------------------------------------------------------------- 
Chest X-ray x 
--------------------------------------------------------------------------------------------------------------------------- 
Hepatitis B, C serology x 
--------------------------------------------------------------------------------------------------------------------------- 
Type III procollagen x    then  every  3   
amino terminal propeptide       months 
(PIIINP)  
a Hb, HCT, erythrocytes, leukocytes, differential blood count, platelets
b ALT, AST, AP, cGT, albumin, bilirubin, lactate dehydrogenase (LDH)
c Liver biopsy instead of a liver sonography in risk groups
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Table 21 Tabular summary
Acitretin
First approved in
Germany
1992 (Psoriasis vulgaris)
Recommended control
parameters
Erythrocyte sedimentation rate (ESR),
complete blood count, liver values,
renal values, blood lipid values,
pregnancy test, x-ray control of the
bones in case of long-term therapy
Recommended initial
dosage
0.3–0.5 mg/kg BW per day for
approximately 4 weeks, then 0.5–
0.8 mg/kg BW
Recommended
maintenance dosage
Individual dosaging dependent on the
results and tolerance
Expected beginning
of clinical effect
After 4–8 weeks
Response rate Widely variable and dose-dependent,
no deﬁnite statement possible,
partial remission (PASI 75) in 25–
75% of the patients (30–40 mg per
day) (LE 3) in studies
Important
contraindications
(limited selection)
Renal and liver damage, desire to have
children in female patients of child-
bearing age, pregnancy, nursing,
alcohol abuse, manifest diabetes
mellitus, wearing of contact lenses,
history of pancreatitis,
hyperlipidemia requiring drug
treatment
Important ADRs (limited
selection)
Hypervitaminosis A (e.g., cheilitis,
xerosis, nose-bleeding, alopecia,
increased skin fragility)
Important drug
interactions (limited
selection)
Phenytoin, tetracyclines, methotrexate,
alcohol, mini-pill
Other Contraception up to 2 years after
discontinuation in female patients of
child-bearing age
Instructions for application 
Pre-treatment
Anamnesis 
Exclusion of pregnancy/nursing
a (patient must be informed 
expressly and extensively about the teratogenic risk of the 
medication, the necessity of effective and long-term contracep-
tion, and the possible consequences of a pregnancy while tak-
ing retinoids); written documentation of the patient informa-
tion interview 
Alcohol consumption (women of child-bearing age may not 
drink alcohol during and up to 2 months after treatment with 
acitretin) 
Exclusion of alcohol abuse 
Question regarding bone aches and aches in joints  
Laboratory controls (see Table 3.5.5.2)
During treatment
With long-term treatment (approximately 1–2 years): radio-
logical control examinations of the spine and joints are rec-
ommended if signs and symptoms develop to exclude possible 
occurrence of ossification 
Reliable contraception
a in women of child-bearing age 
For women of child-bearing age: No alcohol consumption 
during therapy 
Laboratory controls (see Table 3.5.5.2)
Post-treatment
Patients may not donate blood for up to 1 year after the discon-
tinuation of therapy 
Reliable contraception
a in women of child-bearing age up to 2 
years after therapy 
For women of child-bearing age: no alcohol consumption up 
to 2 months after end of therapy 
a Double contraception is recommended (e.g., condom + pill; IUD/Nuva-Ring + pill; cave:
no low-dosed progesterone preparations/mini-pills) during and up to 2 years after the end of
therapy; effectiveness is reduced by acitretin
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Of 52 studies assessed, four fulfilled the Guidelines’ inclusion 
criteria in terms of a monotherapy and another four in terms of a 
combination therapy.
[91-93, 140-143]
As a result of the very heterogeneous study results, it is not possible 
to make a clear statement regarding the efficacy of a monotherapy 
with acitretin (LE 3). 
The effectiveness of retinoids in lower dosages as a monotherapy in 
moderate to severe psoriasis vulgaris is not satisfactory. 
Higher dosages result in an increase of the efficacy, but these are 
frequently accompanied by increased ADRs in the skin and mucous 
membranes. 
In women of childbearing age, the teratogenity, the monthly preg-
nancy tests, and the need for contraception for up to 2 years after 
the termination of the therapy severely limit the use of acitretin. 
An advantage of treatment with retinoids is the synergistic effect in 
combination with UV light. There is, however, insufficient evidence 
available on the basis of the studies included to recommend this 
approach. 
Therapeutic recommendation 
Acitretin is not recommended as a monotherapy because 
of lack of efficacy. 
The application of higher dosages, which are more 
effective, is limited because of frequent adverse drug 
reactions. 
The treatment of plaque psoriasis with acitretin in 
women of child-bearing age is strongly discouraged. 
Other therapies
Climate/balneotherapy
Table 23 Tabular summary
Climate/balneotherapy
First approved in
Germany
Clinical experience with balneotherapy
has existed for more than 200 years
Recommended control
parameters
Regular skin inspection
Recommended initial
dosage
Therapy regimens vary depending on the
institution/location
Recommended
maintenance dosage
Therapy regimens vary depending on the
institution/location
Expected beginning
of clinical effect
Varies greatly
Response rate Varies greatly (LE 4)
Important
contraindications
Dependent on modality selected
Important ADRs Dependent on modality selected
Important drug
interactions
Not applicable
Other Balneotherapy and climate therapy are
frequently combined
General assessment 
Of 33 studies assessed, three fulfilled the Guidelines‘ inclusion 
criteria.
[144-146]. This translates into a level of evidence 4. 
The onset of clinical effect and the response rate vary greatly. For 
that reason, it is not possible to provide exact figures. 
Balneotherapy and climate therapy have been successfully applied 
for the treatment of psoriasis vulgaris for centuries and are fre-
quently used in combination with other therapies. 
These are treatment modalities which have been developed over the 
years, but for which only very preliminary scientific data are avail-
able. 
In the case of a combined strategy using natural phototherapeutic 
principles, efficacy and safety are similar to those of simple photo-
therapy. 
Balneotherapy and climate therapy are tied to certain geographic 
regions and the specialized facilities located there. 
Therapeutic recommendation 
Balneotherapy and climate therapy have a special place 
in the framework of the long-term management of psoria-
sis vulgaris. 
The integration of appropriate therapy phases into the 
treatment concept of patients with psoriasis vulgaris 
requiring treatment for years can be recommended. 
These methods are not indicated for acute treatment or 
short-term therapy. 
Table 22 Laboratory controls during treatment with Acitretin
Period in weeks     Pre-treatment  4  8  16
Diagnostics
--------------------------------------------------------------------------------------------------------------------------- 
Complete blood count
a    x      x  x 
--------------------------------------------------------------------------------------------------------------------------- 
AST, ALT, AP, yGT       x        x  x  x 
--------------------------------------------------------------------------------------------------------------------------- 
Creatinine, urea       x 
--------------------------------------------------------------------------------------------------------------------------- 
Triglycerides, cholesterol, HDL
b  x     x   x 
--------------------------------------------------------------------------------------------------------------------------- 
Pregnancy test (urine) 
(monthly up to 2 years after therapy) x  Monthly 
--------------------------------------------------------------------------------------------------------------------------- 
Fasting blood sugar     x 
a Hb, HCT, leukocytes, platelets
b Preferably assayed twice (week-2 and 0); HDL, high-density lipidoprotein
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General assessment 
Of eight studies evaluated, three fulfilled the Guidelines’ inclusion 
criteria.
[77, 147, 148] This resulted in a level of evidence 4. 
These studies of an additive, psychosocial treatment of psoriasis 
patients with the evidence grade B or C and with a large random 
sample selection as well as a relatively large dropout rates do not 
allow for any final conclusions to be drawn with respect to the 
efficacy of these therapies. 
The low number of adverse events is certainly an advantage. 
With a psychosocial treatment like Psoriasis Symptom Management 
or patient training, direct effects on skin symptoms can be achieved 
through, for example, improved stress management, and indirect 
effects on the development of the psoriasis can be achieved through, 
for example, improved compliance. 
These two forms of therapy should be further investigated empiri-
cally. 
Therapeutic recommendation 
The possible impacts of the disease on social, emotional 
and psychic aspects should be considered for every 
psoriatic patient. 
Information on existing self-help groups is recom-
mended. 
The possibility of participating in a structured training 
program in accordance with the recommendations of the 
ADP (Arbeitsgemeinschaft Dermatologische Präven-
tion) of the DDG should be pointed out. 
If the suffering is very intense or in cases of repeated 
clear exacerbation of the psoriasis vulgaris with stress, 
evaluation by an appropriate specialist with training in 
psychosomatics or psychotherapy can be offered if the 
patient so desires and, if necessary, psychosocial therapy 
initiated.   
Notes on the use of the Guidelines
The presentation of the therapies deliberately focused on
those aspects deemed particularly relevant by a panel of
experts. Aspects which are not of speciﬁc importance for a
certain intervention, but which are part of the physician’s
general obligations to the patient, such as the investigation
of intolerance and allergies toward certain drugs or the
exclusion of contraindications, are not individually listed,
but it is nevertheless taken for granted that these are part of
the physician’s duty to provide care.
It is recommended that each and every user carefully
reads and follows the product information and compare it
with the recommendations in the Guidelines on dosaging,
contraindications, and drug interactions for completeness
and currentness. Every dose or application is administered
at the user’s own risk. The authors and the publishers
kindly request that users inform them of any inaccuracies
that they might notice. The users are requested to keep
themselves constantly informed of any new ﬁndings sub-
sequent to the publication of the Guidelines.
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